Full Press Release Details
AAN April 22, 2026 2026 Kyverna Therapeutics, Inc.
Disclaimer and Forward-Looking Statements This presentation contains
forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the
"Company"). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements include, but are not limited to, statements concerning: the Company's
future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, named-patient access data, ongoing clinical trials, research and development
costs, plans for manufacturing, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations. These forward-looking statements are subject to risks and uncertainties, including the
factors described under the Risk Factors section of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission.
Actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. When evaluating Kyverna's business and prospects, careful consideration should be given to these risks and uncertainties.
These statements speak only as of the date of this presentation, and Kyverna undertakes no obligation to update or revise these statements. This presentation also contains estimates made by independent parties relating to industry market size and
other data. These estimates involve a number of assumptions and limitations and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information, and we do not take any
responsibility for the accuracy or completeness of such information. This presentation contains references to trademarks and marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this presentation may
appear without the or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. The
Company does not intend its use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by any other companies. This presentation includes results from
named-patient basis access. Similar to expanded access or compassionate use in the United States, "IH" or "Individueller Heilversuch," also known as "named-patient basis access," is a regulatory scheme in Germany
that allows for the supply of a treatment that has not received marketing authorization for an individual patient in response to a request by the treating physician on behalf of the named patient. This option can be pursued for the expected benefit
of a patient who has exhausted all available treatment options, under the discretion of the treating physician, with the patient's consent. The use of miv-cel in the IH settings is not a substitute for, or intended to replace, our clinical
trials. The goal is not to assess the effectiveness of a therapy, but rather to provide an individual patient with a possible efficacious approach when all other treatment options have failed, as determined by the patient's physician. While we
do not expect to be able to use the results from these activities as the basis for approval in our applications for marketing approval to the U.S. Food and Drug Administration (FDA) or other foreign regulatory agencies, we believe such activities
may provide additional clinical insights beyond highly focused clinical trials in specific geographies. 2026 Kyverna Therapeutics, Inc. 2
Today's Agenda Speakers Solidifying our Leadership in Autoimmune
CAR T Stiff Person Syndrome (SPS) - Primary Analysis Review Warner Biddle Naji Gehchan, M.D., MSc, MBA Chief Executive Officer Chief Medical & Development Officer Generalized Myasthenia Gravis (gMG) - Phase 2 Data Update Advancing
Valuable Market Opportunity in SPS Amanda Piquet, M.D., FAAN Sri Muppidi M.D. University of Colorado Anschutz Stanford Medicine C line Dion Foundation Endowed Chair Q&A 2026 Kyverna Therapeutics, Inc. 3
Positioned to Deliver the First Approved Autoimmune CAR T, Miv-cel Lead
indications, SPS and gMG, addressing significant unmet medical need Transformative clinical results reinforce potential to change the treatment paradigm by delivering drug-free, disease-free remission with a single dose BLA submission preparations
underway for SPS, a valuable commercial opportunity Phase 3 gMG trial paves way to significant market opportunity underpinned by miv-cel's differentiated clinical profile 2026 Kyverna Therapeutics, Inc. 4
New Data Reinforce Kyverna's Differentiated Neuroimmunology
Franchise Opportunity SPS Registrational Primary Analysis gMG Phase 2 Longer-Term Follow-Up Further supports path to approval & confidence in launch Further supports confidence in Phase 3 Trial Statistically significant, durable
clinical Even deeper responses as data mature, with benefit across all endpoints, with reversal durability out to 52 weeks of disability scores 100% of patients achieved clinically New secondary endpoint results and
meaningful response across MG-ADL, translational data demonstrate full QMG, and MGC spectrum of miv-cel clinical benefit Majority of patients achieved MSE 100% free of immunotherapies and a well-tolerated safety profile SPS - 100%
free of immunotherapies for SPS as of Week 16 and through last follow-up. gMG - 100% free of immunotherapies, including NSISTs, high-dose steroids (>10 mg), and FcRn and complement inhibitors up to 24 weeks. MG-ADL, myasthenia gravis
Activities of Daily Living; MGC, Myasthenia Gravis Composite; MSE, minimal symptom expression; QMG, Quantitative Myasthenia Gravis. 2026 Kyverna Therapeutics, Inc. 5
Miv-cel: Potential First-in-Class and Best-in-Class CAR T Designed for
Potency & Tolerability 1,2 Mivocabtagene Autoleucel (miv-cel) More than 100 patients dosed with Fully Human Autologous CD19 CAR T 3 With CD28 Costim miv-cel across multiple indications Deep and broad depletion of peripheral-
Anti-CD19 scFv and tissue-resident B cells to support broad 4,5 immune reset and durable remission CD8 Hinge 3 No high-grade CRS or ICANS CD8 TM First SPS and gMG patients treated with a single dose of miv-cel achieved
durable CD28 Costim efficacy beyond 24 months without the 6 need for chronic immunotherapies CD3 CRS, cytokine release syndrome; Costim, co-stimulation; gMG, generalized myasthenia gravis; ICANS, immune effector cell-associated neurotoxicity
syndrome; scFv, single-chain fragment variable; TM, transmembrane. 1. Brudno JN, et al. Nat Med. 2020;26:270-280. 2. Alabanza L, et al. Mol Ther. 2017;25:2452-2465. 3.Data on file, Kyverna Therapeutics. 4. Minopoulou I, et al. Ann Rheum
Dis.2025;84(3):e4-e7. 5. Albach FN, et al. 2026 Kyverna Therapeutics, Inc. 6 Rheumatology. 2025;64(6):4075-4077. 6. Named patient access data, Kyverna Therapeutics.
SPS - Primary Analysis Results from KYSA-8 Registrational Trial
Naji Gehchan, M.D., MSc, MBA - Chief Medical and Development Officer Amanda Piquet, M.D., FAAN - University of Colorado Anschutz, C line Dion Foundation Endowed Chair 2026 Kyverna Therapeutics, Inc.
SPS is a Debilitating, Progressive Autoimmune Disease with No
FDA-Approved Therapies SPS impacts the inhibitory signaling Devastating Impact on Patients pathways, which are the body's braking system and the target of 80% of patients lose mobility, needing autoantibodies produced by B 1-3 walking aid
assistance or wheelchair 1,2 cells in SPS Only ~19% of patients remained able 4 Symptoms characterized by muscle to work after 4 years stiffness and painful muscle spasms, 1-3 "Freezing attacks" and sudden falls impacting mobility 1,2
requiring ER care Inadequate response with off-label Risk of permanent disability and symptomatic and immunomodulatory 3 increased mortality 1,2,5 therapies ER, emergency room. 1. Rakocevic G, et al. BMC Neurol. 2019;19:1. 2. Dalakas MC. Nat Rev
Neurol. 2024;20(10):587-601. 3. Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165. 4.NCBI. https://www.ncbi.nlm.nih.gov/sites/books/NBK573078/ 2026 Kyverna Therapeutics, Inc. 9 5. Dalakas MC. Neurol Neuroimmunol Neuroinflamm.
SPS Natural History Study Reinforces Significant Unmet Medical Need
Large, multicenter, retrospective study assessing T25FW in patients with SPS (n=153) Key Takeaways Majority of patients had no or limited (<20%) improvement in T25FW Disability (mRS) did not improve over time Walking aid
use increased over time All patients treated with off-label immunomodulators or symptomatic medication Study Contextualizes Transformative Miv-cel Data and Supports the T25FW as a Valid Longitudinal Measure of Mobility in SPS Newsome SD, et
al. Presented at the 2026 AAN Annual Meeting [abstract 966]. 2026 Kyverna Therapeutics, Inc. 10
Registrational Trial Designed to Support Path to BLA Received Both ODD
and RMAT Designations KYSA-8: Open-label, single-arm, multicenter study N = 26 Primary endpoints: Miv-cel Age 18 to 75 years Change from baseline in T25FW at 16 weeks Low-Dose Cy/Flu Safety Diagnosis of SPS
lymphodepletion One- Inadequate response Secondary endpoints: change from + year to immunomodulatory baseline at 16 weeks Single infusion of therapy Follow 8 1 10 CAR T cells Modified Rankin Scale (mRS) Up Stiffness
index 2 Distribution of Stiffness Index (DSI) Hauser Ambulation Index (HAI) Heightened Sensitivity Scale (HSS) SPS immunotherapies are discontinued Rapid Clinical Enrollment Underscores Significant Unmet Need and
Kyverna's Ability to Execute Cy/Flu, cyclophosphamide and fludarabine; ODD, Orphan Drug Designation; RMAT, Regenerative Medicine Advanced Therapy; T25FW, timed 25-foot walk test. 2026 Kyverna Therapeutics, Inc. 11
Primary Endpoint Outcome Assesses Impact of SPS on Walking Ability
Timed 25-Foot Walk (T25FW) 20% improvement 1 Validated tool to assess walking ability considered clinically 2 1 Used to evaluate stiffness and loss of mobility in SPS meaningful 3 Healthy adults can perform the T25FW in ~4-5
seconds T25FW = Average of 2 Walks FIRST WALK TURN AROUND SECOND WALK 25 FEET START/STOP START/STOP 1. Hobart J, et al. Neurology. 2013; 80: 1509-1517. 2. Newsome SD and Johnson T J. Neuroimmunol. 2022;369:577915. 3. Motl RW, et al. Mult Scler J.
2017; 23(5): 704-710. 2026 Kyverna Therapeutics, Inc. 12
Secondary Endpoint Outcomes Assess Extent of Disability and
SPS-Specific Symptoms Modified Rankin Degree of 0 1 2 3 4 5 6 1 disability No symptoms Nonsignificant Slight Moderate Severe Death Moderately Scale (mRS) Disability Disability Disability Disability Severe Disability Hauser Time and degree of
assistance to Ambulation 0 1 2 3 4 5 6 7 8 9 2 No symptoms Fatigue Abnormal gait No Support Unilateral Unilateral Bilateral Cannot walk Restricted to Restricted to complete T25FW T25FW 10s T25FW 20s support support support 25ft WC WC *
Index (HAI) T25FW 20s T25FW >20s T25FW >20s Frequent WC Can self No self transfer use transfer Distribution-of- Muscle stiffness across body 1 point for each stiff body region (0-6) Stiffness 3,4 regions Index (DSI) Number of
Heightened triggers of 1 point for each trigger/stimulus (1-7) Sensitivity Scale muscle 3,4 (HSS) spasms T25FW, timed 25-foot walk; WC, wheelchair. 1. van Swietin JC, et al. Stroke. 1988; 19(5): 604-607. 2. Hauser SL, et al. New Engl J Med. 1983;
308(4): 173-180. 3. Dalakas MC, et al. N Engl J Med. 2001; 345(26): 1870-1876. 4. Dalakas MC, et al. Ann Neurol. 2017; 82(2): 271-277. 2026 Kyverna Therapeutics, Inc. 13
Primary Endpoint Met: Significant Improvement in T25FW 46% Median
Improvement at Week 16 Significant T25FW Improvement and Reduced Walking Aid Use 81% of patients achieved clinically meaningful improvement ( 20% 1 reduction from baseline) 31% completed T25FW in <5 seconds; P = .0003 2
typical time for healthy adults Of the 12 patients requiring a walking aid for T25FW at baseline, 67% (8/12) no longer needed assistance at week 16 As of week 16 and through last follow- Baseline 35 None 54 12 up, all 26 (100%)
patients remained n=26 Week 16 Unilateral 85 4 12 free of immunomodulatory or n=26 Bilateral 0 20 40 60 80 100 immunosuppressant therapies for SPS* Patients, % *Includes Includes IVIg/SCIg, PLEX, rituximab and/or prednisone ( 20 mg/day) for
SPS symptoms. Data cutoff: 26Nov2025. Percentages may total more than 100% due to rounding. BL, baseline; T25FW, timed 25-foot walk. 14 1. Hobart J, et al. Neurology. 2013;80(16):1509-17. 2. Motl RW, et al. Mult Scler. 2017;23(5):704-710.
Secondary Endpoints Met: Miv-cel Achieved Significant (P < .0001)
Improvements in Disability, Mobility, Stiffness, and Hypersensitivity Modified Rankin Scale Hauser Ambulation Index 0 1 2 3 4 5 6 0 1 2 3 4 5 6 7 8 9 Significant (P < .0001) mean improvements in mRS and HAI of -0.8 (SD, 0.86) and -1.6
(1.13) and SPS- specific measures, DSI and HSS, of -1.5 (1.75) and -3.2 (2.01), respectively 96% of patients (25/26) had improvement in 1 primary or secondary efficacy endpoint Data cutoff: 26Nov2025. Percentages may total more than
100% due to rounding. 15 BL, baseline; DSI, Distribution-of-Stiffness Index; HAI, Hauser Ambulation Scale; HSS, Heightened Sensitivity Scale; mRS, Modified Rankin Scale; wk, week.
Additional Efficacy Measures: Substantial Improvements in Physical and
Mental Functioning 36-Item Short Form Health Survey (SF-36): 6-Minute Walk Test (MWT): >4-fold improvement Week 16 scores comparable to healthy adults 1 over clinical minimally important change 2,3 for most domains 89-meter median improvement at
week 16 Data cutoff: 26Nov2025. 16 1. Oosterveer DM, et al. Mult Scler Relat Disord. 2022;57:103438. 2. Maglinte GA, et al. J Clin Epidemiol. 2012;65(5):497-502. 3. Wu Q, et al. Medicine (Baltimore). 2023;102(24):e33979.
Robust Miv-cel Expansion Led to Complete Peripheral B-cell Depletion
and Significant Reductions in Autoantibody Titers Robust CAR T-cell Expansion Deep B-cell Depletion Reduced GAD65-IgG P < .0001 Median Median 56% IQR IQR median reduction 750 500 250 0 Baseline Week 16 n=20 n=20 CAR-positive T cells
peaked by day 14 54% of patients had B-cell GAD65-IgG was reduced reconstitution by week 16 in 19/20 patients with 20 nM GAD65 at baseline Efficacy was maintained with B-cell reconstitution Data cutoff: 26Nov2025. Box
and whisker plots showing median line (dark line), and interquartile range (box), and min/max (bars). 17 CAR, chimeric antigen receptor; IgG, immunoglobulin G; GAD65, glutamic acid decarboxylase 65. GAD65-IgG by RIA, nmol/L
Miv-cel Treatment Induced Markers of Broad Immune Reset B-Cell
Phenotypes Regulatory T Cells Regulatory T Cells Non-Class Switched Class Switched Na ve Memory Memory Newly emerging B-cell population showed significantly increased Significant increase in na ve phenotype with concomitant
decrease in memory phenotype regulatory T cells at week 16 Data cutoff: 26Nov2025. Box and whisker plots showing median line (dark line), and interquartile range (box), and min/max (bars). 18 IgD, immunoglobulin D.
Miv-cel Demonstrated a Well-Tolerated Safety Profile No
high-grade CRS or ICANS observed Treatment-Related Adverse N=26 Events, n (%) Most common treatment-related AEs were CRS (92%), fatigue (54%), diarrhea (38%), and CRS (any Grade) 24 (92) headache (31%) 10 (38) Grade 1 4 patients had
Grade 3/4 neutropenia, an expected AE with lymphodepletion and CAR T-cell therapies Grade 2 14 (54) All events were manageable with treatment including 3 (12) ICANS (any Grade) G-CSF, fully resolved in 3 patients (median duration of 85
days), and was ongoing in 1 patient Grade 1 3 (12) No serious infections associated with neutropenia 4 (15) Grade 3/4 neutropenia Treatment-related serious AEs occurred in 3 patients; Any treatment-related serious AE 3 (12) all fully
resolved without sequalae Data cutoff: 26Nov2025 CRS and ICANS graded using ASTCT criteria; other AEs graded using CTCAE criteria. 19 AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CAR, chimeric antigen
receptor; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; LD, lymphodepletion.
Potential to Achieve Durable, Drug-Free, Disease-Free Remission and
Reverse Disability In KYSA-8 trial, a single dose of miv-cel resulted in: Significant, robust, rapid improvements in mobility, disability, stiffness, and hypersensitivity 100% free of immunomodulatory or immunosuppressive therapies for SPS as of
last follow-up A consistent, well-tolerated, and manageable safety profile, with the potential for outpatient administration Sustained clinical benefit following deep B-cell depletion and broad immune reset 2026 Kyverna Therapeutics, Inc.
gMG - Updated Data from Phase 2 KYSA-6 Trial Naji Gehchan, M.D.,
MSc, MBA - Chief Medical and Development Officer Sri Muppidi, M.D. - Stanford University 2026 Kyverna Therapeutics, Inc.
Despite Available Treatment Options, High Disease Burden Remains in
Generalized Myasthenia Gravis Current State of Treatment gMG is a B-cell and antibody-mediated for Patients With gMG neuromuscular autoimmune disease that 3,4 causes fluctuating muscle weakness and Inadequate symptom control 1,2 fatigue Few
reach minimal symptom 1,5-6 expression (MSE) Novel therapies are needed that Majority require ongoing minimize or eliminate symptoms of 1-4 immunosuppressant therapy disease while reducing risks associated with chronic immunosuppression Costly and
chronic treatment 1,7 options 1. Howard Jr JF, et al. Lancet Neurol. 2021;20(7):526-536. 2. Vu T, et al. NEJM Evid. 2022;1(5):EVIDoa2100066. 3. DeHart-McCoyle M, et al. BMJ Med. 2023;2(1):e000241. 4. Dewilde S, et al. BMJ Open. 2023;13(1):e066445.
5. AstraZeneca. ULTOMIRIS efficacy data from CHAMPION-MG. https://ultomirishcp.com/gmg/efficacy. Accessed 20 Aug 2025. 6. Vu T, et al. AAN 2025. S34.002. 7. Data on File, Kyverna Therapeutics. 2026 Kyverna Therapeutics, Inc.
KYSA-6: Phase 2/3 Study of Miv-cel in gMG Phase 2 design: Open-label,
single-arm, multicenter study N = 7 Age 18 to 75 years Miv-cel Primary endpoints Diagnosis of gMG, Class IIB-IV per MGFA MG-ADL at 24 weeks criteria Low-Dose Cy/Flu Adverse events Autoantibodies to AChR,